Corporate GovernanceJun 3, 2026, 04:37 PM
Sagimet Biosciences Grants Equity Awards to Top Officers
AI Summary
Sagimet Biosciences Inc. announced that its Compensation Committee and Board of Directors granted stock options and performance-based restricted stock units (PSUs) to its President and CEO David Happel, CFO Thierry Chauche, and Chief Legal and Administrative Officer Elizabeth Rozek on May 28, 2026. The awards were made under the company's 2023 Stock Option and Incentive Plan. Options have an exercise price of $7.27 per share and vest over 48 months, while PSUs are tied to regulatory milestones and vest over a period following their achievement.
Key Highlights
- Sagimet Biosciences granted 300,000 options and 300,000 PSUs to CEO David Happel.
- CFO Thierry Chauche received 50,000 options and 50,000 PSUs.
- Chief Legal and Administrative Officer Elizabeth Rozek received 100,000 options and 100,000 PSUs.
- Options have an exercise price of $7.27 per share, equal to the closing stock price on May 28, 2026.
- Options vest in equal installments over 48 months.
- PSUs are performance-based, earned upon achievement of certain regulatory milestones.
- One-third of earned PSUs vest on the achievement determination date, with the remainder vesting over two years.
Price Impact
More from SGMT